Tony Daltorio: Jim O’Neill, the former chief economist at Goldman Sachs, is best known for coining the BRIC acronym, which stands for the emerging market countries Brazil, Russia, India and China.
But today he is trying to focus the world’s attention on a completely different subject. O’Neill is very concerned about the rising threat that so-called “superbugs” pose. Superbugs are antibiotic-resistant microbes.
O’Neill believes the effects of drug-resistant bacteria on our future world will be very real. His thoughts were revealed in a report issued by a U.K. government-appointed team, which he headed.
He foresees that global gross domestic product growth will be cut by 2% to 3.5% by 2050. That could literally translate to up to $100 trillion – not to mention the cost in possibly millions of human lives if the superbug threat isn’t addressed.
O’Neill is backed up in his concern by the World Health Organization (WHO). It said in a report last April that antibiotic resistance from superbugs is a threat “so serious that it threatens the achievements of modern medicine.” It added that without action, “The world is headed for a post-antibiotic era, in which common infections and minor injuries, which have been treatable for decades, can once again kill.”
More Investments Needed
By action, the WHO means research and development by the pharmaceutical companies on new antibiotics. O’Neill says that as much as $37 billion is needed to incentivize the industry to develop new and innovative drugs to combat the superbug threat.
This money, O’Neill believes, should come in the form of upfront payments from governments. However, the payments would only be made after the antibiotic has been proven effective. That still leaves the pharma companies to foot the initial research costs.
O’Neill is proposing this course of action because there is little market incentive for the companies to do such R&D. Any new drugs developed will only be used after all current treatment options are exhausted.
In other words, the market is too small to interest Big Pharma companies. With such a small market, it may take over a decade of sales for the companies to just cover their development costs. That is the reason why pharmaceutical companies largely moved out of the sector over the past two decades and into more profitable segments, such as cancer treatments.
The once-acknowledged leader in antibiotic research, Pfizer (NYSE:PFE), shut its research operation in 2011. So did Johnson & Johnson (NYSE:JNJ). Eli Lilly (NYSE: LLY) left the field in 2002, as did Sanofi SA (NYSE: SNY) in 2004. Others left in the 1990s.
Pharma Companies to Become Involved
Something has to be done. O’Neill proposes that the industry pool together a $2 billion fund over five years to spur more early stage research on antibiotics.